Our study may also prompt investigators to look deeper into select kinases that phosphorylate AR, such as CDK1/5/9, ACK1, SRC, MAPK (21), as inhibition of these kinases in AR+ prostate cancers may provide patient benefit in combination with AR-targeted agents. Here, CDK1 is linked to prostate cancer.